CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Gilead Sciences has | Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, confirming its retreat from an asset that was ...

AbbVie, Gilead and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the viruses.

The two Rite Aid locations in Yakima are closing and the pharmacy chain’s Union Gap location will soon reopen as a CVS.

CVS released a statement to News 8 and provided more details on its investments, colleague support initiatives, and the acquisition of Rite Aid prescription files.